Indivior Stock Price, News & Analysis

Indivior (Nasdaq: INDV) reported results from a randomized, double-blind trial showing monthly SUBLOCADE extended-release buprenorphine at both 100 mg and 300 mg produced rapid, clinically meaningful reductions in opioid use and improved abstinence in people with moderate-to-severe opioid use disorder.

Participants reduced opioid use from >43 instances/week at screening to <3 instances/week by week 3, a decline maintained through week 38. Post-hoc analyses found the 300-mg maintenance dose achieved significantly higher abstinence in participants with high-frequency fentanyl use. Both doses were well tolerated with no new safety signals; injection-site reactions were more common with 300 mg but were mild-to-moderate and not linked to discontinuation. The post-hoc findings were exploratory and not pre-specified.

Indivior (Nasdaq: INDV) announced on November 20, 2025 that it has concluded a legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million. With receipt of the payment by the DOJ, the resolution agreement will be terminated.

The company said the payment was funded with cash on hand, and management described the milestone as removing a significant liability and simplifying the company's capital structure while reaffirming its compliance commitments.

Indivior (NASDAQ: INDV) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025. Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will join a fireside discussion at 3:30 p.m. ET on the same day. Interested investors should contact their Piper Sandler representative to schedule meetings. The fireside discussion will be publicly available via the Piper Sandler Fireside Chat Live Webcast.

Indivior (Nasdaq: INDV) presented three real-world evidence posters at AMCP Nexus 2025 on Nov 3, 2025 showing clinical and economic benefits of monthly injectable buprenorphine SUBLOCADE for opioid use disorder.

Key findings: lower relapse and recurrence rates, reduced emergency and inpatient use, and substantially lower medical costs in high-adherence patients across Medicaid and commercial cohorts (example: total medical costs ~$23,051 vs $43,357). Analyses also reported lower infectious complications (skin infections -37%, bacteremia -62%) versus transmucosal buprenorphine. Limitations include retrospective claims/EHR design, lack of baseline adjustments, and overlap with the COVID-19 period.

Indivior (NASDAQ: INDV) reported Q3 2025 results and raised full-year guidance on Oct 30, 2025. Total net revenue was $314m in Q3 (+2% YoY) and SUBLOCADE net revenue was $219m (+15% YoY). The company raised FY2025 revenue guidance to $1.18–1.22bn and adjusted EBITDA to $400–420m. Management expects at least $150m of annual operating expense savings beginning 2026 after organizational simplification and ROW optimization. Q3 non-GAAP gross margin was 84% and adjusted EBITDA was $120m. Actions include ROW market exits, discontinuing OPVEE commercial support, and an intended U.S. redomicile.

Indivior (NASDAQ: INDV) will participate in the Stifel 2025 Healthcare Conference in New York City.

Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will appear in a public fireside discussion on Thursday, November 13, 2025 at 8:40 a.m. U.S. EST. Interested investors should contact their Stifel representative to schedule meetings. The fireside discussion will be available via a public webcast.

Indivior (Nasdaq: INDV) will report its third quarter 2025 financial results on Thursday, October 30, 2025 at 7:00 a.m. U.S. ET. Following the release, CEO Joe Ciaffoni and other leaders will host a live webcast presentation at 8:00 a.m. U.S. ET. The live webcast and presentation materials will be available on the company's Investors page at www.indivior.com, with a live webcast link and telephone registration option provided for participants. A replay of the presentation will be posted on www.indivior.com after the event.

Indivior (Nasdaq: INDV) published multicenter, open-label trial results in JAMA Network Open on Oct 15, 2025 showing that rapid SUBLOCADE induction (single 4 mg oral buprenorphine followed by same-day SUBLOCADE injection) was well tolerated and produced higher retention at the second injection versus standard induction (≥7 days oral buprenorphine before first injection).

Benefits were seen across the study population and were especially pronounced among fentanyl-positive participants. Administering the second SUBLOCADE injection one week after the first was well tolerated and the safety profile up to injection two was comparable between arms. Study limitations include its open-label design, which could introduce reporting bias.

Indivior (Nasdaq: INDV) has announced plans to change its corporate domicile from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc. (IPI) as the new U.S. parent company. This strategic move follows the company's Nasdaq listing in June 2023 and subsequent delisting from the London Stock Exchange in July 2025.

The redomiciliation will be implemented through a U.K. court-sanctioned scheme of arrangement, where shareholders will receive one new IPI share for each Indivior PLC share. The transaction requires shareholder approval at an extraordinary general meeting in early December 2025, with the scheme expected to become effective in late January 2026. IPI shares will continue trading on Nasdaq under the symbol INDV.